BesarabA, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584–590.10.1056/NEJM199808273390903)| false
MacdougallIC, Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2016; 89:28–39.10.1016/j.kint.2015.10.002)| false
It is now seven years since the KDIGO guideline on anemia management in chronic kidney disease (CKD) was published in August 2012 (1). To accuse KDIGO of being lazy and idle in generating any updates or revisions would be inappropriate on two accounts.
First, and most important, there has really not been enough truly robust scientific data that would dramatically alter the evidence base from the previous version of the anemia guideline, in which the four NEJM “biggies” on erythropoiesis stimulating agent (ESA) therapy were reviewed and critiqued by the evidence review team: US Normal Hematocrit